Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.

Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Yang Y, Medeiros M, Zaknoen SL.

J Clin Oncol. 2015 Jan 10;33(2):189-94. doi: 10.1200/JCO.2014.55.5789. Epub 2014 Dec 1.


Therapeutic potential of ERK5 targeting in triple negative breast cancer.

Ortiz-Ruiz MJ, Álvarez-Fernández S, Parrott T, Zaknoen S, Burrows FJ, Ocaña A, Pandiella A, Esparís-Ogando A.

Oncotarget. 2014 Nov 30;5(22):11308-18.


A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Gitlitz BJ, Bernstein E, Santos ES, Otterson GA, Milne G, Syto M, Burrows F, Zaknoen S.

J Thorac Oncol. 2014 Apr;9(4):577-82. doi: 10.1097/JTO.0000000000000082.


Potent antimyeloma activity of a novel ERK5/CDK inhibitor.

Álvarez-Fernández S, Ortiz-Ruiz MJ, Parrott T, Zaknoen S, Ocio EM, San Miguel J, Burrows FJ, Esparís-Ogando A, Pandiella A.

Clin Cancer Res. 2013 May 15;19(10):2677-87. doi: 10.1158/1078-0432.CCR-12-2118. Epub 2013 Mar 26.


Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.

Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ, Brekken RA.

Clin Cancer Res. 2012 Sep 15;18(18):5031-42. doi: 10.1158/1078-0432.CCR-12-0453. Epub 2012 Jul 24.


Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.

St John MA, Wang G, Luo J, Dohadwala M, Hu D, Lin Y, Dennis M, Lee JM, Elashoff D, Lawhon T, Zaknoen SL, Burrows FJ, Dubinett SM.

Br J Cancer. 2012 Aug 7;107(4):707-12. doi: 10.1038/bjc.2012.203. Epub 2012 Jul 24.


Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.

Kirane A, Toombs JE, Larsen JE, Ostapoff KT, Meshaw KR, Zaknoen S, Brekken RA, Burrows FJ.

Carcinogenesis. 2012 Sep;33(9):1639-46. doi: 10.1093/carcin/bgs195. Epub 2012 Jun 7.


Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.

Reckamp K, Gitlitz B, Chen LC, Patel R, Milne G, Syto M, Jezior D, Zaknoen S.

Cancer. 2011 Feb 15;117(4):809-18. doi: 10.1002/cncr.25473. Epub 2010 Oct 4.


A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.

Forster M, Kaye S, Oza A, Sklenar I, Johri A, Cheung W, Zaknoen S, Gore M.

Clin Cancer Res. 2007 Jul 15;13(14):4178-84.


Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.

Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR.

Cancer. 2005 Aug 1;104(3):561-9.


Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.

Newlands ES, Foster T, Zaknoen S.

Br J Cancer. 2003 Jul 21;89(2):248-51.


Phase II trial of temozolomide in patients with progressive low-grade glioma.

Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE 2nd, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS.

J Clin Oncol. 2003 Feb 15;21(4):646-51.


A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.

Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL.

Neuro Oncol. 2002 Oct;4(4):261-7. doi: 10.1093/neuonc/4.4.261.


A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.

Sharma S, Kemeny N, Kelsen DP, Ilson D, O'Reilly E, Zaknoen S, Baum C, Statkevich P, Hollywood E, Zhu Y, Saltz LB.

Ann Oncol. 2002 Jul;13(7):1067-71.


Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.

Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS.

Neuro Oncol. 2001 Oct;3(4):246-50. doi: 10.1093/neuonc/3.4.246.


Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S.

Ann Oncol. 2001 Feb;12(2):259-66.


A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA.

Br J Cancer. 2000 Sep;83(5):588-93.


Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA.

J Clin Oncol. 1999 Sep;17(9):2762-71. Erratum in: J Clin Oncol 1999 Nov;17(11):3693.


Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma.

White JD, Zaknoen SL, Kasten-Sportès C, Top LE, Navarro-Roman L, Nelson DL, Waldmann TA.

Cancer. 1995 Apr 1;75(7):1598-607.


T-cell receptor gene rearrangement in T-cell large granular leukocyte leukemia: preferential V alpha but diverse J alpha usage in one of five patients.

Kasten-Sportès C, Zaknoen S, Steis RG, Chan WC, Winton EF, Waldmann TA.

Blood. 1994 Feb 1;83(3):767-75.


The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia.

Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, Roessler E, Horak ID, Zaknoen S, Kasten-Sportes C, et al.

Blood. 1993 Sep 15;82(6):1701-12.


The interleukin-2 receptor: a target for immunotherapy.

Waldmann TA, Goldman C, Top L, Grant A, Burton J, Bamford R, Roessler E, Horak I, Zaknoen S, Kasten-Sportes C, et al.

Ann N Y Acad Sci. 1993 Jun 23;685:603-10. Review. No abstract available.


The interleukin-2 receptor: a target for immunotherapy.

Waldmann TA, Goldman C, Top L, Grant A, Burton J, Bamford R, Roessler E, Horak I, Zaknoen S, Kasten-Sportes C, et al.

Adv Exp Med Biol. 1992;323:57-66. Review. No abstract available.


Immunoregulatory cell dysfunction in chronic B-cell leukemias.

Zaknoen SL, Kay NE.

Blood Rev. 1990 Sep;4(3):165-74. Review.


An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura.

Hoffman R, Zaknoen S, Yang HH, Bruno E, LoBuglio AF, Arrowsmith JB, Prchal JT.

N Engl J Med. 1985 May 2;312(18):1170-4. No abstract available.


Supplemental Content

Loading ...
Support Center